Literature DB >> 26346864

Spatial predisposition of dysplasia in Barrett's esophagus segments: a pooled analysis of the SURF and AIM dysplasia trials.

Cary C Cotton1, Lucas C Duits2, W Asher Wolf1, Anne F Peery1, Evan S Dellon1, Jacques J Bergman2, Nicholas J Shaheen1.   

Abstract

OBJECTIVES: Surveillance endoscopy detects dysplasia within Barrett's esophagus (BE) and dictates treatment. Current biopsy regimens recommend uniformly spaced random biopsies. We assessed the distribution of dysplasia in BE to develop evidence-based biopsy regimens.
METHODS: We performed analysis of the distribution of dysplasia within BE using pretreatment biopsy data from two randomized controlled trials (RCTs) of radiofrequency ablation for dysplastic BE: the SURF (Surveillance vs. Radiofrequency Ablation) trial and the AIM Dysplasia (Ablation of Intestinal Metaplasia (AIM) Containing Dysplasia) trial. We used generalized linear models with generalized estimating equations (GEE) to estimate prevalence differences for dysplasia depending on the standardized location of biopsies. We performed Monte Carlo simulation of biopsy regimens to estimate their yield for any dysplasia within segments.
RESULTS: Dysplasia preferentially resides in the proximal-most half of the BE segment that is almost twice as likely to demonstrate dysplasia as the distal-most quartile. In pooled analysis, compared with the distal-most quarter, the prevalence difference in the proximal-most quarter was 22.6%, in the second proximal-most quarter 23.1%, and in the second distal-most quarter 15.3%. The best performing biopsy regimen in simulation studies acquired 8 biopsies in the most proximal cm of BE, 8 biopsies in the second cm, and 2 biopsies in each cm thereafter (q1cm: 8, 8, 2, 2…). A slightly simpler q2cm (every 2 cm) regimen (q2cm: 12, 12, 4…) was nearly as effective.
CONCLUSIONS: The post hoc analysis of two RCTs reveals a substantially increased prevalence of dysplasia proximally in BE segments. Our simulations suggest an altered biopsy regimen could increase sensitivity of biopsies in short-segment BE by >30%.

Entities:  

Mesh:

Year:  2015        PMID: 26346864      PMCID: PMC4785998          DOI: 10.1038/ajg.2015.263

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  37 in total

1.  Relationship between gastro-oesophageal reflux pattern and severity of mucosal damage.

Authors:  A J Bredenoord; G J M Hemmink; A J P M Smout
Journal:  Neurogastroenterol Motil       Date:  2009-04-13       Impact factor: 3.598

2.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

Review 3.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 4.  Developing a nonendoscopic screening test for Barrett's esophagus.

Authors:  Sudarshan Kadri; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  Biomark Med       Date:  2011-06       Impact factor: 2.851

5.  The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus.

Authors:  John A Evans; Dayna S Early; Norio Fukami; Tamir Ben-Menachem; Vinay Chandrasekhara; Krishnavel V Chathadi; G Anton Decker; Robert D Fanelli; Deborah A Fisher; Kimberly Q Foley; Joo Ha Hwang; Rajeev Jain; Terry L Jue; Khalid M Khan; Jenifer Lightdale; Phyllis M Malpas; John T Maple; Shabana F Pasha; John R Saltzman; Ravi N Sharaf; Amandeep Shergill; Jason A Dominitz; Brooks D Cash
Journal:  Gastrointest Endosc       Date:  2012-12       Impact factor: 9.427

6.  Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett's esophagus.

Authors:  Viraj C Kariyawasam; Michael J Bourke; Luke F Hourigan; Gary Lim; Alan Moss; Stephen J Williams; Scott B Fanning; Adrian M Chung; Karen Byth
Journal:  Gastrointest Endosc       Date:  2012-03-03       Impact factor: 9.427

7.  Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy.

Authors:  Edoardo Savarino; Radu Tutuian; Patrizia Zentilin; Pietro Dulbecco; Daniel Pohl; Elisa Marabotto; Andrea Parodi; Giorgio Sammito; Lorenzo Gemignani; Giorgia Bodini; Vincenzo Savarino
Journal:  Am J Gastroenterol       Date:  2009-12-08       Impact factor: 10.864

8.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

9.  The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol.

Authors:  Revital Kariv; Thomas P Plesec; John R Goldblum; Mary Bronner; Mary Oldenburgh; Thomas W Rice; Gary W Falk
Journal:  Clin Gastroenterol Hepatol       Date:  2008-12-13       Impact factor: 11.382

10.  Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study.

Authors:  Victoria H Coupland; William Allum; Jane M Blazeby; Michael A Mendall; Richard H Hardwick; Karen M Linklater; Henrik Møller; Elizabeth A Davies
Journal:  BMC Cancer       Date:  2012-01-12       Impact factor: 4.430

View more
  7 in total

1.  Assessment of Barrett's esophagus and dysplasia with ultrahigh-speed volumetric en face and cross-sectional optical coherence tomography.

Authors:  Osman O Ahsen; Kaicheng Liang; Hsiang-Chieh Lee; Michael G Giacomelli; Zhao Wang; Benjamin Potsaid; Marisa Figueiredo; Qin Huang; Vijaysekhar Jayaraman; James G Fujimoto; Hiroshi Mashimo
Journal:  Endoscopy       Date:  2018-09-27       Impact factor: 10.093

2.  Shining a White Light on Barrett's Esophagus: What Does the BING Classification Bring?

Authors:  Shajan Peter
Journal:  Dig Dis Sci       Date:  2017-10       Impact factor: 3.199

3.  Early Barrett esophagus-related neoplasia in segments 1 cm or longer is always associated with intestinal metaplasia.

Authors:  Benjamin Michael Allanson; Jessica Bonavita; Bob Mirzai; Tze Sheng Khor; Spiro C Raftopoulos; Willem Bastiaan de Boer; Ian S Brown; Marian Priyanthi Kumarasinghe
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

4.  What is the optimal surveillance strategy for non-dysplastic Barrett's esophagus?

Authors:  Ying Gibbens; Prasad G Iyer
Journal:  Curr Treat Options Gastroenterol       Date:  2020-06-25

5.  Length of Barrett's segment predicts failure of eradication in radiofrequency ablation for Barrett's esophagus: a retrospective cohort study.

Authors:  Tyler Luckett; Chaitanya Allamneni; Kevin Cowley; John Eick; Allison Gullick; Shajan Peter
Journal:  BMC Gastroenterol       Date:  2018-05-21       Impact factor: 3.067

6.  Longitudinal and Circumferential Distributions of Dysplasia and Early Neoplasia in Barrett's Esophagus: A Pooled Analysis of Three Prospective Studies.

Authors:  Kara L Raphael; Sumant Inamdar; Matthew J McKinley; Nichol Martinez; Kimberly Cavaliere; Allon Kahn; Cadman L Leggett; Prasad Iyer; Kenneth K Wang; Arvind J Trindade
Journal:  Clin Transl Gastroenterol       Date:  2021-02-22       Impact factor: 4.488

7.  The SpaTemp cohort: 168 nondysplastic Barrett's esophagus surveillance patients with and without progression to early neoplasia to evaluate the distribution of biomarkers over space and time.

Authors:  N F Frei; K Konté; L C Duits; E Klaver; F J Ten Kate; G J Offerhaus; S L Meijer; M Visser; C A Seldenrijk; E J Schoon; B L A M Weusten; B E Schenk; R C Mallant-Hent; J J Bergman; R E Pouw
Journal:  Dis Esophagus       Date:  2021-03-08       Impact factor: 2.822

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.